Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Real-world experience: ide-cel for R/R multiple myeloma

Doris Hansen • 4 Jun 2022
ASCO 2022
Multiple Myeloma CAR-T Idecabtagene vicleucel
KarMMa

Doris K. Hansen, MD, Moffitt Cancer Center, Tampa, FL, provides an overview of the real-world outcomes of patients with relapsed/refractory (R/R) multiple myeloma treated with standard of care idecabtagene vicleucel (ide-cel) under the commercial FDA label. Despite more patients being penta-refractory and less fit compared to the pivotal KarMMa trial (NCT03361748), safety and 30-day responses in the real-world setting are comparable to the clinical trial population. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Doris Hansen

5:08
A pro-inflammatory state & peak cytokines are associated with ide-cel toxicity & responses in MM
Doris Hansen • 5 Dec 2023
3:15
Comparing TTNT or death between front-line DRd and VRd in transplant-ineligible multiple myeloma
Doris Hansen • 5 Dec 2023
2:18
A cost per responder analysis of cilta-cel vs physician's choice in lenalidomide-refractory MM
Doris Hansen • 5 Dec 2023
2:06
Managing and treating CRS, neurological toxicity and cytopenias associated with CAR-T therapy
Doris Hansen • 14 Feb 2023

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals